Telix grows portfolio with US buy

Posted 9 February 2024 AM

Melbourne-based Telix Pharmaceuticals has signed a deal to buy US-based QSAM Biosciences to gain control of an investigational next-generation radiopharmaceutical.

The drug, Samarium-153-DOTMP, has two major potential applications: pain management of bone metastases and osteosarcoma therapy, including in paediatric patients. It has a shorter half-life and lower average beta energy compared to competing products, which allows a more controlled radiation dose and the ability to give multiple doses more frequently for optimal and prolonged palliation effect.

To see the whole article, please login